Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus; a Phase Ib Clinical Trial and Associated Mechanistic Studies
Phase of Trial: Phase I
Latest Information Update: 01 Sep 2017
At a glance
- Drugs Tofacitinib (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- 22 Jun 2016 Status changed from not yet recruiting to recruiting.
- 16 Jun 2016 Status changed from recruiting to not yet recruiting.
- 02 Sep 2015 New trial record